guidance.fyi
Company, quarter, or anything said on a call

Q1 FY27 earnings callLaxmi Dental Limited

Laxmi Dental achieved its highest-ever quarterly revenue and profitability, driven by strong growth across its dental lab and aligner solutions businesses.

Positive tone4 min readPublished 7 days after the call

Numbers
MetricThis quarterChangeFive-quarter trend
RevenueINR74.7 crores13.9%
EBITDAINR14.4 crore20.6%
EBITDA Margin19.2%
PATINR10.3 crores23.8%
PAT Margin13.8%
Dental Lab Growth y-o-y23.5%
International Business Growth y-o-y37.4%
Aligner Business Growth y-o-y28.6%
TL;DR
  • Revenue was INR74.7 crores, a 13.9% y-o-y growth, marking the highest-ever quarterly revenue.
  • EBITDA grew 20.6% y-o-y to INR14.4 crores with margin improving to 19.2%; PAT grew 23.8% to INR10.3 crores.
  • Dental lab business grew 23.5% y-o-y, with international growth at 37.4%.
  • Aligner business grew 28.6% y-o-y, with Kids-e-Dental segment up 54.4%.
  • Planned investment in new machinery and acquisition of land in Palghar for a new owned facility.
  • Scanner deployment target for FY27 is 800 to 1,000 units, with average price around INR3 lakhs.
Said on the call

“This was our highest ever quarterly revenue.”

Sameer Merchant
From the Q&A
TopicWhat management said
Customer DifferentiationManagement cited 36 years of trust, global quality standards, and being the only branded player in the crown category as key reasons dentists choose Laxmi Dental.
Scanner Margins & StrategyScanners have a trading margin of 15% to 20%, causing minor fluctuations; excluding scanners, margins are stable and rising. The target is to deploy 800 to 1,000 scanners in FY27 at an average price of INR3 lakhs.
Capacity UtilizationAligner capacity utilization is around 70%, while lab capacity is at a constant threshold of 90%-95% due to its custom nature.
New Land AcquisitionThe land in Palghar is for transitioning from leased facilities to an owned one to improve workflow efficiency, control costs, and support future scalability; no disruption is expected during the move.
Domestic Lab Growth OutlookDomestic lab growth was 12% y-o-y; management expects growth to accelerate in coming quarters due to scanner deployment maturity and satellite labs.
AI-Led Automation ExpensesHigher other expenses were partly due to initial AI-related costs for beta models, but these are expected to reduce as the company scales.
Aligner Business StrategyThe company sells only through dentists (B2B), not directly to patients (B2C), and does not segregate between orthodontists and general dentists.
Guidance
  • Aspiration for revenue growth is 15% to 20%.
  • Aspiration for EBITDA margin is 18% to 20%.
  • Plan to deploy 800 to 1,000 scanners in FY27.
  • Investments planned in new machinery and a new owned facility in Palghar to modernize and expand capacity.
Source
Also this week
  • Zydus Lifesciences LimitedQ1 FY27Positive tone

    Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.

    ZYDUSLIFEPharmaceuticals & Healthcare4 min read
  • Gufic Biosciences LimitedQ1 FY27Positive tone

    Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.

    GUFICBIOPharmaceuticals & Healthcare4 min read
  • Dishman Carbogen Amcis LimitedQ1 FY27Positive tone

    Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.

    DCALPharmaceuticals & Healthcare3 min read
  • Q1 FY27 saw strong revenue and profit growth driven by scaling service business (Patient Support Programs) and strategic investments beginning to yield results.

    QMSMEDIPharmaceuticals & Healthcare3 min read
  • Natco Pharma LimitedQ1 FY27Positive tone

    Strong profit growth driven by a bumper flu season in the associate Adcock Ingram and double-digit growth in the base business.

    NATCOPHARMPharmaceuticals & Healthcare4 min read